Exact Sciences Corporation (EXAS) M&A Call Transcript
Exact Sciences Corporation ( EXAS ) M&A Call November 20, 2025 9:00 AM EST Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Travis Steed - BofA Securities, Research Division Presentation Operator Good morning, and thank you for standing by.
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Exact Sciences Corporation ( EXAS ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. I think we're good to go here.
Exact Sciences Corporation (EXAS) Presents at 7th Annual Healthcare Symposium Transcript
Exact Sciences Corporation ( EXAS ) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants David Harding Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. Carri Chan Asia Chang Noam Krantz - Guardant Health, Inc. Alexis Tosti Henry Wei George Stoupakis Presentation Kevin Dreyer GAMCO Investors, Inc. All right. Is my mic on?
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
Here is how Exact Sciences (EXAS) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
Earnings Estimates Rising for Exact Sciences (EXAS): Will It Gain?
Exact Sciences (EXAS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exact Sciences (EXAS) is an Intriguing Medical Stock to Watch After Q3 Earnings
Recognized as a leader in medical diagnostics, the upside potential for Exact Sciences (EXAS) stock has been lifted by its improved operational and financial performance.
Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript
Exact Sciences Corporation ( EXAS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Derek Leckow - Vice President of Investor Relations Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Bradley Bowers - Mizuho Securities USA LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Douglas Schenkel - Wolfe Research, LLC Andrew Brackmann - William Blair & Company L.L.C.
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?
Here is how Exact Sciences (EXAS) and EssilorLuxottica Unsponsored ADR (ESLOY) have performed compared to their sector so far this year.
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
